Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
This approval marks a major step forward in the treatment of obesity, as it allows for easier integration of GLP-1 therapy into a patients daily routine
bariatric procedure volumes declined 11.4% in 2025 reversing a two-decade growth trend as semaglutide and tirzepatide provide comparable weight loss outcomes for class I and class II obesity without surgical risk, recovery time, or nutritional deficiency complications
A restaurant industry buffeted so far this decade by a global pandemic, rising prices, supply disruption and worker shortages now has a new challenge looming
doi: 10.1097/MD.0000000000005768 225 JiSYLiuXMLiBTZhangYLLiuHBZhangYCet al
These benefits are driven in large part by type 2 diabetes outcomes, where cost offsets from fewer hospitalizations and complications outweigh drug costs
